THANK YOU FOR SUBSCRIBING
The acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals.
FREMONT, CA: Germany-based leader in animal health, Boehringer Ingelheim acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company for an undisclosed amount. GST is dedicated to the research, development, and production of evidence-based, regenerative medicines (stem cell therapies) to treat orthopedic and metabolic diseases in animals. Boehringer Ingelheim had previously entered into a partnership with GST in 2018 and launched Arti-Cell® Forte in Europe in 2019.
“Collaboration with external partners plays an essential role in helping us expand our portfolio. After two years of a very successful partnership, we have decided to acquire GST. We are convinced that its expertise in the field of state-of-the art stem cell products will help us bring even more innovative solutions to our customers,” said Jean-Luc Michel, Head of Global Strategic Marketing, Boehringer Ingelheim Animal Health.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Arti-Cell Forte is testimony to the innovation strength that lies within both companies. It is the first-ever stem cell product in the veterinary world granted marketing authorization by the European Commission. The acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals.
“Boehringer Ingelheim wants to lead a new wave of innovation in the veterinary field. This ambition is a natural fit with GST’s management, staff and vision. From the very beginning we aimed to change the veterinary field, a role we will continue to play as a new R&D division within Boehringer Ingelheim,” said Jan Spaas, CEO of GST.
GST is dedicated to the research, development, and production of evidence-based, regenerative medicines (stem cell therapies) used to treat orthopedic and metabolic diseases in animals. “This decision is fully aligned with our recently refocused strategic direction. Stem cell research areas and regenerative medicine offer an exciting potential for the next wave of innovation we are actively pursuing. In addition, strengthening external partnerships to accelerate our innovative efforts and growth is one of the key elements of our strategy,” adds Eric Haaksma, Head of Global Innovation at Boehringer Ingelheim Animal Health.
Check Out This: Government Tech Startups
More in News